Combining IBI351 with chemotherapy for advanced lung cancer with KRAS G12C mutation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase Ib/III study evaluates the efficacy and safety of IBI351, a small molecule inhibitor, in combination with various chemotherapy regimens for patients with advanced non-squamous non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation. The study includes five treatment cohorts, each receiving different combinations of IBI351 with chemotherapy agents such as pemetrexed, carboplatin, and Cetuximab. Participants must have unresectable or metastatic disease and have not previously received systemic antitumor therapy for their condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically confirmed diagnosis of nonsquamous NSCLC with KRAS G12C mutation
2. Unresectable or metastatic disease
3. Adequate organ function
4. Not received any systemic antitumor therapy for locally advanced or metastatic non-squamous NSCLC previously.

Exclusion Criteria:

1. History of intestinal disease or major gastric surgery or inability to swallow oral medications
2. Prior therapy with agents targeting KRAS G12C mutation (e.g., AMG 510).
3. Active brain metastases.

Where it's running

• Jilin Province Cancer Hospital
  Jilin City, Changchun, China Recruiting

Study contacts

• Study coordinator: Haiyan Zhu
• Email: haiyan.zhu@innoventbio.com
• Phone: 0512-69566088

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors

  This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.

  Recruiting at 2 sites Phase 1 Novartis · Darlinghurst, New South Wales and 1 other locations · NCT07801508

• Long-term survival and AI-based prediction in NSCLC patients treated with immunotherapy

  This study tests whether AI analysis of routine pathology images, along with multi-omics data, can predict long-term survival for people with advanced NSCLC treated with immunotherapy.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07668037

• Tislelizumab use in European patients with NSCLC or ES-SCLC in routine care

  This study looks at how tislelizumab is used in real-world European patients with advanced NSCLC or extensive-stage SCLC and what outcomes are seen in everyday clinical practice.

  Recruiting at 6 sites BeOne Medicines · Córdoba and 5 other locations · NCT07652736

• Lorlatinib with local consolidation therapy for ALK-positive advanced non-small cell lung cancer

  This trial will test whether adding local consolidation treatments to lorlatinib helps people with ALK-positive advanced non-small cell lung cancer stay progression-free longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07415005

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• Firmonertinib versus standard EGFR drugs as first treatment for advanced NSCLC with EGFR PACC mutations

  This trial tests whether daily firmonertinib works better than standard EGFR drugs (osimertinib or afatinib) as the first treatment for people with advanced NSCLC that has EGFR PACC mutations.

  Recruiting at 141 sites Phase 3 ArriVent BioPharma, Inc. · Fullerton, California and 140 other locations · NCT07185997

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.